Search research articles
Contact Us
Filters
Showing results (441-450 of 940) with videos related to
Page
of 94
Sort By:
Neuro-Oncology Advances
|
August 11, 2022
Associations of levetiracetam use with the safety and tolerability profile of chemoradiotherapy for patients with newly diagnosed glioblastoma
Katharina Seystahl, Felix Boakye Oppong, Emilie Le Rhun, et al.
Neuro-Oncology
|
December 20, 2015
Predicting outcome of epilepsy after meningioma resection
Hans-Georg Wirsching, Corinne Morel, Corinne Gmür, et al.
Pharmacoepidemiology and Drug Safety
|
April 21, 2012
Comparative evaluation of the drug interaction screening programs MediQ and ID PHARMA CHECK in neurological inpatients
Olesya I Zorina, Patrick Haueis, Alexander Semmler, et al.
Journal of Neuro-Oncology
|
September 10, 2018
Post-operative cardiovascular complications and time to recurrence in meningioma patients treated with versus without pre-operative embolization: a retrospective cohort study of 741 patients
Hans-Georg Wirsching, Johannes Konstantin Richter, Felix Sahm, et al.
Cancer Research
|
April 6, 2006
Regeneration and tolerance factor: a novel mediator of glioblastoma-associated immunosuppression
Patrick Roth, Steffen Aulwurm, Isabella Gekel, et al.
Journal of Neuro-Oncology
|
March 19, 2010
Genetic variants of folate and methionine metabolism and PCNSL incidence in a German patient population
Delia Kurzwelly, Stefan Knop, Markus Guenther, et al.
Neurology
|
August 17, 2012
Outcome of elderly patients with primary CNS lymphoma in the G-PCNSL-SG-1 trial
Patrick Roth, Peter Martus, Philipp Kiewe, et al.
Neuro-Oncology Practice
|
March 20, 2025
Temozolomide chemotherapy for patients with newly diagnosed glioblastoma in the CENTRIC EORTC 26071-22072 and CORE trials: Does time of administration matter?
Marjolein Geurts, Luzia Berchtold, Franz Koenig, et al.
Neuro-Oncology
|
June 24, 2024
No benefit from TMZ treatment in glioblastoma with truly unmethylated MGMT promoter: Reanalysis of the CE.6 and the pooled Nordic/NOA-08 trials in elderly glioblastoma patients
Monika E Hegi, Felix B Oppong, James R Perry, et al.
Journal of Neuro-Oncology
|
March 5, 2011
Temozolomide and 13-cis retinoic acid in patients with anaplastic gliomas: a prospective single-arm monocentric phase-II study (RNOP-05)
Oliver Grauer, Christina Pascher, Christian Hartmann, et al.
Page
of 94
Search research articles
Search
Showing results (441-450 of 940) with videos related to
Sort By:
Page
of 94
Neuro-Oncology Advances
|
August 11, 2022
Associations of levetiracetam use with the safety and tolerability profile of chemoradiotherapy for patients with newly diagnosed glioblastoma
Katharina Seystahl, Felix Boakye Oppong, Emilie Le Rhun, et al.
Neuro-Oncology
|
December 20, 2015
Predicting outcome of epilepsy after meningioma resection
Hans-Georg Wirsching, Corinne Morel, Corinne Gmür, et al.
Pharmacoepidemiology and Drug Safety
|
April 21, 2012
Comparative evaluation of the drug interaction screening programs MediQ and ID PHARMA CHECK in neurological inpatients
Olesya I Zorina, Patrick Haueis, Alexander Semmler, et al.
Journal of Neuro-Oncology
|
September 10, 2018
Post-operative cardiovascular complications and time to recurrence in meningioma patients treated with versus without pre-operative embolization: a retrospective cohort study of 741 patients
Hans-Georg Wirsching, Johannes Konstantin Richter, Felix Sahm, et al.
Cancer Research
|
April 6, 2006
Regeneration and tolerance factor: a novel mediator of glioblastoma-associated immunosuppression
Patrick Roth, Steffen Aulwurm, Isabella Gekel, et al.
Journal of Neuro-Oncology
|
March 19, 2010
Genetic variants of folate and methionine metabolism and PCNSL incidence in a German patient population
Delia Kurzwelly, Stefan Knop, Markus Guenther, et al.
Neurology
|
August 17, 2012
Outcome of elderly patients with primary CNS lymphoma in the G-PCNSL-SG-1 trial
Patrick Roth, Peter Martus, Philipp Kiewe, et al.
Neuro-Oncology Practice
|
March 20, 2025
Temozolomide chemotherapy for patients with newly diagnosed glioblastoma in the CENTRIC EORTC 26071-22072 and CORE trials: Does time of administration matter?
Marjolein Geurts, Luzia Berchtold, Franz Koenig, et al.
Neuro-Oncology
|
June 24, 2024
No benefit from TMZ treatment in glioblastoma with truly unmethylated MGMT promoter: Reanalysis of the CE.6 and the pooled Nordic/NOA-08 trials in elderly glioblastoma patients
Monika E Hegi, Felix B Oppong, James R Perry, et al.
Journal of Neuro-Oncology
|
March 5, 2011
Temozolomide and 13-cis retinoic acid in patients with anaplastic gliomas: a prospective single-arm monocentric phase-II study (RNOP-05)
Oliver Grauer, Christina Pascher, Christian Hartmann, et al.
Page
of 94